
Southwest Airlines is taking generic drugmakers to court and accusing more than 20 companies of price fixing that inflated costs for millions of Americans, including its own employees. In this episode of The Biotech Brief, we unpack the lawsuit, the history of generic drug cartel behavior, and why drug developers (yes, even biotech innovators) should be paying close attention. This episode explores how drug pricing moves from boardroom strategy to national scandal.
Version: 20241125
No comments yet. Be the first to say something!